Abstract
Objectives:
The purpose of this study was to develop an individually tailored, non-pharmacological treatment model, the Cognitive Model for Behavioral Interventions (CoMBI), for patients with Behavioral and Psychological Symptoms of Dementia (BPSD) and comorbid maladaptive personality traits (CMPT), and to explore its feasibility and effectiveness.
Methods:
CoMBI was developed and implemented in two geriatric psychiatric inpatient wards in the Netherlands. In this single-group pretest-posttest, feasibility study, 40 patients with BPSD and CMPT (M = 73.8, SD = 8.5) were treated with CoMBI. BPSD and CMPT were assessed using informant-based questionnaires. Wilcoxon signed-rank tests and effect size calculations were conducted to determine differences.
Results:
Wilcoxon signed-rank tests demonstrated a significant decrease of BPSD with medium (r = 0.45) to large (r = 0.56) effect sizes. CoMBI demonstrated high acceptability and compliance by health-care professionals and family members.
Conclusions:
CoMBI is a feasible treatment model for challenging behavior in patients with BPSD and CMPT. CoMBI is associated with a significant decrease in challenging behaviors regardless of etiology.
Clinical implications:
Focusing on personality and associated core needs could have a key role in the non-pharmacological treatment of the elderly with BPSD.
Netherlands Trial Register (Trial NL6478/NTR6665).
The purpose of this study was to develop an individually tailored, non-pharmacological treatment model, the Cognitive Model for Behavioral Interventions (CoMBI), for patients with Behavioral and Psychological Symptoms of Dementia (BPSD) and comorbid maladaptive personality traits (CMPT), and to explore its feasibility and effectiveness.
Methods:
CoMBI was developed and implemented in two geriatric psychiatric inpatient wards in the Netherlands. In this single-group pretest-posttest, feasibility study, 40 patients with BPSD and CMPT (M = 73.8, SD = 8.5) were treated with CoMBI. BPSD and CMPT were assessed using informant-based questionnaires. Wilcoxon signed-rank tests and effect size calculations were conducted to determine differences.
Results:
Wilcoxon signed-rank tests demonstrated a significant decrease of BPSD with medium (r = 0.45) to large (r = 0.56) effect sizes. CoMBI demonstrated high acceptability and compliance by health-care professionals and family members.
Conclusions:
CoMBI is a feasible treatment model for challenging behavior in patients with BPSD and CMPT. CoMBI is associated with a significant decrease in challenging behaviors regardless of etiology.
Clinical implications:
Focusing on personality and associated core needs could have a key role in the non-pharmacological treatment of the elderly with BPSD.
Netherlands Trial Register (Trial NL6478/NTR6665).
| Original language | English |
|---|---|
| Pages (from-to) | 903-914 |
| Journal | Clinical Gerontologist |
| Volume | 45 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2022 |
Keywords
- AGE-NEUTRALITY
- AGITATION
- ALTERNATIVE MODEL
- CoMBI
- DIAGNOSTIC-ACCURACY
- DSM-5
- INVENTORY
- NONPHARMACOLOGICAL INTERVENTIONS
- PERSONALITY-DISORDERS
- PREMORBID PERSONALITY
- PSYCHOMETRIC PROPERTIES
- behavioral therapyI
- bpsd
- caregiver
- dementia
- disruptive behavior
- neurocognitive disorders
- non-pharmacological intervention
- older adults
- personality